Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis
Xuezhen Zeng(Sun Yat-sen University), Alfred S.L. Cheng(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), John Wong(Chinese University of Hong Kong), Jingying Zhou(Ningbo University Affiliated Hospital), Sui Peng(Sun Yat-sen University), Stephen L. Chan(Chinese University of Hong Kong), Jing Xue(Zhejiang University), Joseph J.�Y. Sung(Nanyang Technological University), Ka‐Fai To(Chinese University of Hong Kong), Ming Kuang(Kunming Medical University), Myth T.S. Mok(Chinese University of Hong Kong), Shun-Wa Tsang(Hong Kong University of Science and Technology), Wenshu Tang(Chinese University of Hong Kong), Hector Kwong-Sang Wang(Hong Kong University of Science and Technology), Philip Chun Yeung(Chinese University of Hong Kong), Zhewen Xiong(Chinese University of Hong Kong), Qiang Xia(Shanghai Jiao Tong University), Xiao Chen(Sun Yat-sen University), Jun Yu(Yueyang Second People's Hospital), Yu Feng(Central South University of Forestry and Technology), Weiqin Yang(Chinese University of Hong Kong), Man Liu(Chinese University of Hong Kong), Jing Wang(Chinese University of Hong Kong), Anthony W.H. Chan(Chinese University of Hong Kong), King-Lau Chow(Hong Kong University of Science and Technology), Hanyong Sun(Shanghai Jiao Tong University), Jingqing Li(Sun Yat-sen University)
Cited by 46
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k